Status:
COMPLETED
A Study to Evaluate the Efficacy and Safety of AD-223
Lead Sponsor:
Addpharma Inc.
Conditions:
Hypertension,Essential
Eligibility:
All Genders
19+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of AD-223
Detailed Description
Condition or disease : hypertension
Eligibility Criteria
Inclusion
- Signed informed consent
- Other inclusions applied
Exclusion
- Orthostatic hypotension with symptom
- Other exclusions applied
Key Trial Info
Start Date :
February 15 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 2 2025
Estimated Enrollment :
502 Patients enrolled
Trial Details
Trial ID
NCT06052748
Start Date
February 15 2024
End Date
April 2 2025
Last Update
April 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hanyang University Hospital
Seoul, South Korea